The role of pharmacogenetics in the disposition of and response to tacrolimus in solid organ transplantation
DA Hesselink, R Bouamar, L Elens… - Clinical …, 2014 - Springer
The calcineurin inhibitor tacrolimus is the backbone of immunosuppressive drug therapy
after solid organ transplantation. Tacrolimus is effective in preventing acute rejection but has …
after solid organ transplantation. Tacrolimus is effective in preventing acute rejection but has …
Pharmacology and toxicology of mycophenolate in organ transplant recipients: an update
This review aims to provide an update of the literature on the pharmacology and toxicology
of mycophenolate in solid organ transplant recipients. Mycophenolate is now the …
of mycophenolate in solid organ transplant recipients. Mycophenolate is now the …
Pharmacogenetic aspects of the use of tacrolimus in renal transplantation: recent developments and ethnic considerations
JT Tang, LM Andrews, T van Gelder… - Expert opinion on …, 2016 - Taylor & Francis
ABSTRACT Introduction: Tacrolimus (Tac) is effective in preventing acute rejection but has
considerable toxicity and inter-individual variability in pharmacokinetics and …
considerable toxicity and inter-individual variability in pharmacokinetics and …
Pharmacologic treatment of transplant recipients infected with SARS-CoV-2: considerations regarding therapeutic drug monitoring and drug–drug interactions
L Elens, LJ Langman, DA Hesselink… - Therapeutic drug …, 2020 - journals.lww.com
Background: COVID-19 is a novel infectious disease caused by the severe acute respiratory
distress (SARS)-coronavirus-2 (SARS-CoV-2). Several therapeutic options are currently …
distress (SARS)-coronavirus-2 (SARS-CoV-2). Several therapeutic options are currently …
[HTML][HTML] Long-term clinical impact of adaptation of initial tacrolimus dosing to CYP3A5 genotype
N Pallet, I Etienne, M Buchler, E Bailly… - American Journal of …, 2016 - Elsevier
Pretransplantation adaptation of the daily dose of tacrolimus to CYP3A5 genotype is
associated with improved achievement of target trough concentration (C 0), but whether this …
associated with improved achievement of target trough concentration (C 0), but whether this …
Kidney Transplant Recipients Carrying the CYP3A4*22 Allelic Variant Have Reduced Tacrolimus Clearance and Often Reach Supratherapeutic Tacrolimus …
N Pallet, AS Jannot, M El Bahri, I Etienne… - American Journal of …, 2015 - Wiley Online Library
CYP3A4* 22 is an allelic variant of the cytochrome P450 3A4 associated with a decreased
activity. Carriers of this polymorphism may require reduced tacrolimus (Tac) doses to reach …
activity. Carriers of this polymorphism may require reduced tacrolimus (Tac) doses to reach …
Predictors of tacrolimus pharmacokinetic variability: current evidences and future perspectives
AL Degraeve, S Moudio, V Haufroid… - Expert opinion on …, 2020 - Taylor & Francis
Introduction In kidney transplantation, tacrolimus (TAC) is at the cornerstone of current
immunosuppressive strategies. Though because of its narrow therapeutic index, it is critical …
immunosuppressive strategies. Though because of its narrow therapeutic index, it is critical …
[HTML][HTML] Pharmacogenetics and drug-induced nephrotoxicity in renal transplant recipients
An external file that holds a picture, illustration, etc. Object name is BI-5-45-g003. jpg
Introduction: The advent of calcineurin inhibitors (CNIs), as the leading immunosuppressive …
Introduction: The advent of calcineurin inhibitors (CNIs), as the leading immunosuppressive …
Clinical implementation of pharmacogenetics in kidney transplantation: calcineurin inhibitors in the starting blocks
L Elens, R Bouamar, N Shuker… - British Journal of …, 2014 - Wiley Online Library
Pharmacogenetics has generated many expectations for its potential to individualize therapy
proactively and improve medical care. However, despite the huge amount of reported …
proactively and improve medical care. However, despite the huge amount of reported …
Personalizing initial calcineurin inhibitor dosing by adjusting to donor CYP3A‐status in liver transplant patients
K Monostory, K Tóth, Á Kiss, E Háfra… - British Journal of …, 2015 - Wiley Online Library
Aims Inter‐individual variability in dose requirements of calcineurin inhibitors (CNI) has
been linked to genetic polymorphisms of CYP3A enzymes. CYP3A5* 3, CYP3A4* 1B and …
been linked to genetic polymorphisms of CYP3A enzymes. CYP3A5* 3, CYP3A4* 1B and …